Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/74
C12N-001/20
C12R-001/225
A23L-033/18
A23L-033/135
A23C-009/123
C07K-014/335
A61K-038/00
출원번호
US-0537565
(2014-11-10)
등록번호
US-RE46912
(2018-06-26)
우선권정보
KR-10-2006-0073722 (2006-08-04)
국제출원번호
PCT/KR2007/002363
(2007-05-14)
§371/§102 date
20100317
(20100317)
국제공개번호
WO2008/016214
(2008-02-07)
발명자
/ 주소
Kang, Ji Hee
You, Byeung I.
Yun, Sung I.
Park, Han O.
출원인 / 주소
BIONEER CORPORATION
대리인 / 주소
Sughrue Mion, PLLC
인용정보
피인용 횟수 :
0인용 특허 :
6
초록▼
The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity a
The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.
대표청구항▼
1. A Lactobacillus gasseri BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 2. The Lactobacillus gasseri BNR17 strain according to claim 1, wherein the s
1. A Lactobacillus gasseri BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 2. The Lactobacillus gasseri BNR17 strain according to claim 1, wherein the strain contains 16S rRNA sequence represented by SEQ ID NO: 1. 3. A composition containing an effective dose of the Lactobacillus gasseri BNR17 of claim 1. 4. The composition according to claim 3, wherein the composition is selected from the group consisting of food, food additive, animal feed and animal feed additive. 5. The composition according to claim 4, wherein the animal feed additive contains at least one selected from the group consisting of other non-pathogenic microorganisms, enzymes and a mixture thereof. 6. A pharmaceutical composition comprising an effective dose of the Lactobacillus gasseri BNR17 of claim 1strain in an enteric coating, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 7. A culture solution of the Lactobacillus gasseri BNR17 of claim 1. 8. A method for inhibiting weight gain comprising administering to a subject an effective doseamount of the Lactobacillus gasseri BNR17 of claim 1strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 9. A fermented food product comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 10. The fermented food product according to claim 9, wherein the fermented food product is a dairy product. 11. A fermented food product having a bacterial component, the bacterial component consisting essentially of Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 12. The fermented food product according to claim 11, wherein the fermented food product is a dairy product. 13. A dry powder comprising live Lactobacillus gasseri cells and a protectant that inhibits death of the Lactobacillus gasseri cells during a drying step, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, and wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder. 14. A food product comprising the dry powder of claim 13. 15. A feed product for a non-human animal comprising an animal feedstock and Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 16. A tablet or capsule comprising the dry powder of claim 13. 17. The tablet or capsule according to claim 16, wherein the tablet or capsule further comprises a pharmaceutically acceptable carrier or excipient. 18. A formulation comprising Lactobacillus gasseri BNR17 strain, a diluent, a high-fiber additive, an encapsulant, and a lipid, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 19. A method for treating obesity or inhibiting weight gain in an adult human, the method comprising administering to the human a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 20. A method for inhibiting saccharide absorption in an adult mammal, the method comprising administering to the mammal a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 21. A method for inhibiting weight gain or treating obesity in a non-human mammal, comprising administering to the mammal a composition comprising Lactobacillus gasseri BNR17 strain, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 22. The method according to claim 21, comprising administering 0.1-10 g/day of the Lactobacillus gasseri BNR17. 23. The pharmaceutical composition according to claim 6, wherein the L. gasseri BNR17 strain inhibits weight gain. 24. The dry powder of claim 13, wherein the protectant further comprises 10 weight % trehalose, 10 weight % maltodextrin, and 7.5 weight % lactose. 25. The feed product of claim 15, wherein the feed product further comprises one or more selected from the group consisting of a diluent, a high-fiber additive, an encapsulant, a lipid, an enzyme and a non-pathogenic microorganism. 26. The feed product of claim 25, wherein the enzyme is selected from the group consisting of phytase, cellulose, xylase, maltase, invertase, and a combination thereof. 27. The feed product of claim 25, wherein the non-pathogenic organism is Aspergillus oryzae. 28. A method of producing a food product, comprising mixing a dry powder comprising live Lactobacillus gasseri cells and a protectant that inhibits death of the Lactobacillus gasseri cells during a drying step, with a food, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 29. The method of claim 28, wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (6)
Kuma,Yoshiharu; Akahoshi,Ryoichi; Kudo,Tatsuyuki; Kawami,Kojiro; Shibata,Miku; Hashimoto,Shinji, Fermented milk drinks and foods and process for producing the same.
Park, Han Oh; Bang, Young Bae; Joung, Hea Jung; Kim, Bong Cheol; Kim, Hang Rae, Lactobacillus KCTC 0774BP and acetobacter KCTC 0773BP for treatment or prevention of obesity and diabetes mellitus.
Song, Su Han; Kang, Sun Kyung; Kim, Jae Ho; Park, Young Hyun; Park, Han Oh, Microorganisms for preventing and/or treating obesity or diabetes mellitus.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.